Narrative updates are currently in beta.

Back to narrative

Update shared on29 Jul 2025

Fair value Increased 10%
AnalystConsensusTarget's Fair Value
HK$13.51
29.0% overvalued intrinsic discount
29 Jul
HK$17.42
Loading
1Y
283.7%
7D
-0.9%

The consensus price target for InnoCare Pharma has increased to HK$13.51, underpinned by notable improvements in net profit margin and higher future P/E expectations.


What's in the News


  • InnoCare received IND approval to initiate a clinical trial for its novel B7-H3 targeted ADC (ICP-B794) for various solid tumors, further strengthening its solid tumor pipeline alongside other precision medicine candidates like zurletrectinib.
  • Latest oncology pipeline updates presented at major conferences highlighted strong efficacy and safety of mesutoclax (BCL2 inhibitor) in combination with orelabrutinib for CLL/SLL, and promising trial results for treatments in marginal zone lymphoma and diffuse large B-cell lymphoma (DLBCL), with high response and survival rates.
  • The anti-CCR8 antibody (ICP-B05) showed encouraging efficacy and safety in advanced CTCL, while zurletrectinib continued to demonstrate robust and durable responses in NTRK+ advanced solid tumors.
  • Minjuvi® (tafasitamab), a CD19-targeting antibody, in combination with lenalidomide, has received NMPA approval as the first CD19 antibody therapy for relapsed/refractory DLBCL in China.
  • Mesutoclax was granted Breakthrough Therapy Designation and IND approval in China for R/R mantle cell lymphoma and myeloid malignancies, with accelerated Phase III development underway for CLL/SLL.

Valuation Changes


Summary of Valuation Changes for InnoCare Pharma

  • The Consensus Analyst Price Target has significantly risen from HK$12.25 to HK$13.51.
  • The Future P/E for InnoCare Pharma has significantly risen from 52.06x to 72.32x.
  • The Net Profit Margin for InnoCare Pharma has significantly risen from 16.22% to 17.99%.

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.